Search
pemigatinib (Pemazyre)
Indications:
- unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement
Dosage:
- 13.5 mg orally once daily for 14 consecutive days followed by 7 days off i 21-day cycles
- continue treatment until disease progression or unacceptable toxicity
- Swallow tablet whole, with or without food
Tabs: 4.5 mg, 9 mg, & 13.5 mg
Monitor:
- ophthalmoscopy including optical coherence tomography
- prior to initiation of therapy
- every 2 months for the first 6 months of treatment
- every 3 months thereafter,
Adverse effects:
- >= 20%:
- hyperphosphatemia, hypophosphatemia
- diarrhea, constipation, dysgeusia, nausea, vomiting, stomatitis
- dry eye, dry mouth, arthralgia, abdominal pain, back pain
- alopecia, nail toxicity, dry skin
- fatigue, decreased appetite
- serious: retinal pigment epithelium detachment
Drug interactions:
- strong or moderate cyp3A inducers or inhibitors
Mechanism of action:
- tyrosine kinase inhibitor
- targets FGFR1, FGFR2 & FGFR3 with IC50 values of < 2 nM
Interactions
drug adverse effects of tyrosine kinase inhibitor(s)
General
small inhibitory antineoplastic agent (ib drug)
tyrosine kinase inhibitor
Database Correlations
PUBCHEM cid=86705695
References
- Pubchem: 86705695
- HIGHLIGHTS OF PRESCRIBING INFORMATION
PEMAZYRETM (pemigatinib) tablets, for oral use
https://www.pemazyre.com/pdf/prescribing-information.pdf